Medicenna's Trial Underway Using Brainlab Drug Delivery Technology

Medicenna Therapeutics (TSXV:MDNA) and Brainlab jointly announced recurrent patients from their Phase 2b trial of  MDNA55 have been treated at three clinical centers using drug delivery technology from Brainlab.
As quoted in the press release:

The investigators used convection enhanced delivery (CED) to inject MDNA55, together with an imaging agent, directly into the tumor. When combined with real-time image guided MRI, CED allows delivery of MDNA55 at high concentrations into the tumor tissue while avoiding exposure to the rest of the body. The current Phase 2b clinical trial plans to enroll 43 adult patients with rGB at leading brain cancer centers in the United States.
Precise targeting is an integral part in the treatment of brain tumors to achieve significant coverage. iPlan^® Flow planning software from Brainlab helps determine trajectories for drug infusions while VarioGuide^®, a universal instrument holder, is then used to guide the drug delivery device into place for treatment.
“Brainlab brings advanced tools for planned and controlled delivery to this trial. Standardization of the surgical workflow is a critical component of consistent patient treatment and for obtaining optimal clinical trial data,” commented Rowena Thomson, Drug Delivery Manager at Brainlab. “With Medicenna, we have found one of the most experienced teams for targeted drug delivery as a key partner in the development of therapies for brain tumors. Using iPlan Flow and VarioGuide, neurosurgeons will be able to plan treatments and catheter placement for delivery and distribution of MDNA55.”

Click here to read the full press release.

Source: www.newswire.ca